Superworth

Anaptysbio price to free cash flow ANAB

Market value divided by free cash flow over the last twelve months, since 2021.

Today, Oct 23, 2026
n/m
a quarter missing
5-year median
112×
5-year range
53.9× to 438×
Peer median
8.1×

Anaptysbio's price to free cash flow can't be checked today: its free cash flow for Q4 FY26, the quarter to Jun 30, 2026, is missing from our data, so the twelve months it rests on can't be added up.

On the days it had one over the last 5 years, its median was 112×, from 53.9× in Feb 2022 to 438× in Jul 2026.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far80.9×76.3×438×
2025n/m a value too high to mean anything
2024n/m a value too high to mean anything
2023n/m a value too high to mean anything
202254.4×53.9×60.7×
202162.5×54.0×168×

Against its peers

Companies in Drug Manufacturers - General nearest Anaptysbio's size, closest first, today.

CompanyPrice to free cash flow
ANABAnaptysbion/m
PCRXPacira BioSciences8.1×
PAHCPhibro Animal Health160×
ANIPANI Pharmaceuticals9.6×
OMEROmerosn/m
AMPHAmphastar Pharmaceuticals7.0×
HRMYHarmony Biosciencesn/m
PBHPrestige Consumer Healthcare9.6×
ABUSArbutus Biopharman/m
NRIXNurix Therapeutics7.5×
COLLCollegium Pharmaceutical2.3×
Peer median8.1×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Anaptysbio

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.